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Up to 7% of breast cancer cases in North America are estimated to
be due to mutations in predisposing breast cancer genes (Claus
et al, 1996; Newman et al, 1998). It is estimated that from 1 in 850
to 1 in 500 individuals carry a mutation in either of the highly
penetrant breast and ovarian cancer susceptibility genes BRCA1 or
BRCA2 (Easton et al, 1993; Ford et al, 1995). Women who carry a
mutation in the BRCA1 gene have a 56–87% risk of developing
breast cancer and a 16–60% risk of developing ovarian cancer by
age 70 (Ford et al, 1994; Easton et al, 1995; Struewing et al, 1997).
Over 300 different mutations in the BRCA1 gene have been
reported to the Breast Cancer Information Core (BIC) database
(BIC, 1998), but the number of different mutations in a defined
ethnic group may be restricted. Although more are anticipated,
specific populations for which mutations in BRCA1 and BRCA2
have been described include Austria, Netherlands and Belgium,
Iceland, Sweden, Hungary, Russia and other Eastern European
nations, as well as the Ashkenazi Jewish and French Canadian
populations (Johannesdottir et al, 1996; Neuhausen et al, 1996;
Tonin et al, 1996, 1998; Gayther et al, 1997; Peelen et al, 1997;
Petrij-Bosch et al, 1997; Ramus et al, 1997; Szabo and King,
1997). The most common BRCA1 mutation among Europeans, the
5382insC mutation, was found in about 79% of breast–ovarian
cancer families in Russia (Gayther et al, 1997). The BRCA1
5382insC mutation was previously found in a West Lothian (South
East) kindred and in an isolated case of breast cancer in Scotland
(Mullen et al, 1997). The mutant haplotype was found to be
identical to that reported in all other apparently unrelated
breast–ovarian cancer families across Europe, with the exception
of marker D17S1327 for the West Lothian family. This may repre-
sent a different origin for the West Lothian family than the Baltic
region than other 5382insC families (Mullen et al, 1997).
Frequent mutations in an ethnically restricted population are
due to a founder effect. Founder effects may be most prominent in
isolated populations that undergo rapid expansion from a limited
number of ancestors. The most frequently reported mutation in the
BIC database is the BRCA1 185delAG (BIC, 1999). This mutation
is estimated to be present in 1% of the Ashkenazi Jewish popula-
tion and has been reported in North America, Israel, Iran, Iraq and
Europe (Struewing et al, 1995; Roa et al, 1996; Szabo and King,
1997). The reconstruction of haplotypes bearing common muta-
tions, such as the 185delAG, provided evidence for strong founder
effects (Simard et al, 1994; Neuhausen et al, 1996). In the UK, the
185delAG mutation was found in three Yorkshire families
(Neuhausen et al, 1996; Xu et al, 1997). The Yorkshire families
were found to share a haplotype that differed from the Ashkenazi
Jewish haplotype (Neuhausen et al, 1996; Xu et al, 1997). This
was evidence of a separate origin or founder for the BRCA1
185delAG mutation in the Ashkenazi Jewish population and the
Yorkshire families.
The BRCA1 2800delAA mutation was first reported in 1994 in a
breast-ovarian cancer family of Scottish descent in the US
(Friedman et al, 1994). In 1995, Boyd et al described a Glasgow
breast cancer patient as homozygous for the 2800delAA mutation.
More recently, Peto et al (1999) studied the prevalence of BRCA1
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cancer patients (under age 46), regardless of family history. Peto
et al (1999) detected the BRCA1 2800delAA mutation in a patient
from Glasgow. To explore the possibility that the 2800delAA
represents a population-specific BRCA1 mutation, we collected
information and DNA specimens on 17 apparently unrelated
BRCA1 2800delAA families across North America and Scotland.
Genotype analysis was performed using five polymorphic
microsatellite markers on chromosome 17q to determine whether
this mutation represents a founder effect.
SUBJECTS AND METHODS
Identification of families with 2800delAA
The Breast Cancer Information Core Database (1997, 1998) was
searched for all entries with the BRCA1 2800delAA mutation. At
the time, nine entries were found from four different centres for
the 2800delAA (Table 1). Communication with genetics clinics in
North America identified four additional families. The majority of
families were tested through clinical service following referral for
genetic counselling and risk assessment. These families typically
had evidence of genetic predisposition to breast cancer (e.g. two
first- or second-degree relatives diagnosed with breast cancer
below age 50 or ovarian cancer). One Toronto family (UT10872)
was identified by a population-based study of unselected ovarian
cancer cases in the province of Ontario. One Scottish family
(USt97) was among fifty unselected breast cancer cases diagnosed
below age 50 in South East Scotland. Three families had been
reported previously; two from Seattle (UW1, UW109) (Friedman
et al, 1994) and one from Glasgow (UG475) (Boyd et al, 1995).*
Where possible, cancer diagnoses were confirmed by retrieval of
pathology or medical records. Detailed family history information
was collected for each kindred.
Controls
Control DNA was obtained from healthy Scottish blood donors via
the South Eastern Scotland Blood Transfusion Service. In addi-
tion, 50 unrelated individuals (e.g. spouses from within affected
families) were tested for the 2800delAA.
Mutation detection
Like the majority of BRCA1 mutations reported thus far, the
2800delAA leads to truncation of the mutant protein and predicted
loss of function. A variety of methods can be applied to initially
detect the presence of a BRCA1 mutation (Friedman et al, 1995).
The deletion of two adenine nucleotides in the BRCA1 sequence of
exon 11 (2800delAA) results in an in-frame stop codon at
nucleotide 2820. The chain-terminating mutation in exon 11 may
be screened by protein-truncation test (PTT) or by single-strand
conformational analysis (SSCA) or by a restriction enzyme assay
as the mutation creates a new Tth recognition site. Mutant bands
were confirmed with direct sequencing of the exon 11 region.
Genotyping markers in the BRCA1 region
Human genomic DNA was isolated from 20–30 ml EDTA or ACD
blood samples. Five polymorphic microsatellite markers located
on chromosome 17q either within BRCA1 or within 250 kb of it
were used to construct genotypes (Friedman et al, 1994). These
markers were used in non-radioactive polymerase chain reaction
(PCR) using 20 cycles, run on sequencing-type gel elec-
trophoresis, then transferred to nylon membranes blotted with 32P
labelled oligo (CA) or with a 32P labelled primer if the locus was
not a dinucleotide repeat. From centromere to telomere, the order
reported in the Genome Database (GDB) is as follows: D17S1321,
D17S855, D17S1322, D17S1323, D17S1327. The total distance
covered by these five markers is 405 kb. Primer sequences to
amplify these markers can be retrieved on-line from the GDB. A
physical map for these markers has been previously resolved
(Neuhausen et al, 1996): D17S1321-(255 kb)-D17S855-(5 kb)-
D17S1322-(45 kb)-D17S1323-(100 kb)-D17S1327
Registrar General for Scotland
Complete and informative records of all Scottish births, marriages
and deaths, dating from the introduction of compulsory registra-
tion in 1855, are held in Register House, Edinburgh, along with
many much older, though incomplete, genealogical data sets.
These are public records, so that the construction of accurate
multi-generation family trees presents fewer problems than is the
case in many countries (Collyer and De Mey, 1987; Sinclair,
1990). Using these records we explored the possibility of an ances-
tral link between the 17 families. Two of these families are thought
to be related as they are known to be descended from ancestors
with the same unusual surname, born in the same part of Scotland
around 1850. Other families were not linked through genealogy
records.
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Table 1 BIC database summary sheet for >8 entries of suspected British origin (November 1999)
BRCA1 mutation Exon Entries Centres Ethnicity
G546T (E143X) 7 10 1 Irish, Western Europe
1294del40 11a 15 6 British, Irish
2080delA 11b 12 6 Dutch, British
2800delAA 11c 11 6 British, Scottish
T3053G (Y978X) 11c 9 4 Irish, Iraqi
3875del4 11d 26 11 Dutch, British, Czech
4184del4 11d 30 12 British, French, Indian, Pakistani
C4446T (R1443X) 13 38 13 British, French, Fr. Can., Belgian, Dutch
*Like USt97, she was ascertained through a survey of early onset breast cancers and,
like US97, she has no known family history of breast or related cancers. Hence the
penetrance of this mutation may be overestimated by selecting cases on the basis of
family history. We are grateful to the authors of that report for their cooperation in
providing additional information.RESULTS
Each of the 17 families contained at least two cases of breast
cancer diagnosed at age 50 or below, or ovarian cancer at any age,
with the exception of family USt97 with only one case of
premenopausal breast cancer confirmed (Table 2). The average age
of onset of breast cancer was 43 (range 25–77) and the average age
of ovarian cancer was 57 (range 39–65). On average, there were
five women affected with breast cancer observed per family. Nine
of the 17 families had bilateral breast cancer cases. There were no
cases of male breast cancer reported in any family. Ten of the 17
families contained cases of ovarian cancer (range 1–3 cases). Eight
of these ten ovarian cancer families contained women diagnosed
with primary cancers of the breast and ovary. Family UW1
included one case of primary cancer of the fallopian tube at age 48.
Of the 17 families, eight contained prostate cancer, including four
families with two cases of prostate cancer. In general, mutation
status was not available for members of a family affected with
cancers other than breast and ovarian cancer, with the exception of
three cases (fallopian tube, colon and prostate cancers in UW1).
The characteristics of the 17 families with the 2800delAA muta-
tion are summarized in Table 2. The genotype observed for the
17 families was in concordance with the previous reports by
Friedman et al (1994, 1995) for two Seattle families (UW1,
UW109). The genotype for the polymorphic microsatellite
markers D17S1321-D17S855-D17S1322-D17S1323-D17S1327
was 14–5–5–6–12 for the DNA samples tested belonging to the
17 BRCA1 2800delAA families (Figure 1). This genotype was
observed for all DNA samples of mutation carriers tested
belonging to the 17 families. It was possible to establish phase
unambiguously for six families (UW1, UG475, UC9214, UT9213,
UT9151, UE2) where multiple family members had participated in
genetic studies. Although phase was not established for the
remaining 11 families the genotype observed was consistent. Six
North American families reported Scottish ancestry. In four of the
North American families, the index case reported ancestry from
the British Isles.
Seven families from Scotland were among 150 multi-case
kindreds tested through the clinical genetics services. Of 50
unselected breast cancer cases presenting under the age of 50 in
the South East region, one was found to have the 2800delAA
mutation in BRCA1 (USt97). Of 50 unrelated individuals (e.g.
spouses) tested in our series, none had the BRCA1 2800delAA
mutation. DNA samples collected on population-based controls in
Scotland were tested specifically for the BRCA1 2800delAA.
Molecular analysis did not detect the 2800delAA mutation in any
of the 100 non-cancer control samples tested.
Figure 1 depicts a representative BRCA1 2800delAA families
UV5763, UW109, UC9214, UT9151, UT10872 and UT271.
Figure 2 depicts family UG475 previously reported by Boyd et al
(1995) with a homozygous BRCA1 2800delAA mutant (indicated
as proband in pedigree). This family was also found to have a
BRCA2 8297delC mutation, detected in the maternal cousin of the
proband. For Table 2, information regarding the maternal cousin
with the BRCA2 8297delC mutation was excluded.
DISCUSSION
The presence of specific BRCA1 or BRCA2 mutations is dependent
in part on the population from which the breast and ovarian cancer
families are ascertained, emphasizing the importance of founder
Scottish BRCA1 founder mutation 707
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Figure 1 Pedigrees of families UV5763, UW109, UC9214, UT9151, UT9213, UT10872 and UT271. Black circles indicate women affected with breast or
ovarian cancer. Squares indicate men. Grey circles and squares indicate individuals affected with cancers other than breast or ovarian cancer. Diagonal slash
indicates deceased. Ov = ovarian cancer, Br = breast cancer, Pr = prostate cancer, Pa = pancreatic cancer, Bl = bladder cancer, Cx = cervical cancer,
St = stomach cancer, Lu = lung cancer, Sk = skin cancer, Te = testicular cancer, Rh = rhabdomyosarcoma, Psu = primary site of cancer unknown. The numbers
following the abbreviations indicate ages of diagnosis. The plus sign indicates the presence of the BRCA1 2800delAA mutation. The associated haplotype for
polymorphic microsatellite markers D17S1321–D17S855–D17S1322–D17S1323–D17S1327 of 14–5–5–6–12 is indicated below the symbols of the individuals
genotypedmutations in population-specific studies (Neuhausen et al, 1996;
Szabo and King, 1997). In particular, haplotype and genotype
analysis provides evidence that a specific BRCA1 or BRCA2 muta-
tion can be associated with the geographic or ethnic origin of the
study population. This knowledge is relevant not only for the
country of origin of the common founder, but also for immigrant
populations. Many European BRCA1 and BRCA2 mutations have
been observed in the USA or Canada, reflecting migration patterns
to North America.
The most common BRCA1 mutations found in British breast-
ovarian cancer families to date have been the 1294del40,
4184del4, C4446T, 3875del4 and 2800delAA mutations (Table 1).
There were between 11 and 38 entries for each of these BRCA1
mutations in the BIC Database (BIC, 1999). The C4446T mutation
was reported frequently and families were of British, Belgian,
French and French-Canadian descent (Neuhausen et al, 1996;
Tonin et al, 1998). The 4184del4 mutation is reported in numerous
families in North America and Europe (BIC, 1998). Previous
genotype analysis for BRCA1 4184del4 mutation families found
diversity in the haplotypes which was not surprising considering
the families were of British, French, Indian and Pakistani descent
(Friedman et al, 1995; Neuhausen et al, 1996; Szabo and King,
1997). In Wales, four BRCA1 (4184del4, 2011insT, 2594delC,
1997del4) and two BRCA2 (4075delGT, 6287del4) mutations were
detected in eight breast cancer families, including two families
with the BRCA1 4184del4 mutation and two families with the
2594delC mutation (Lancaster et al, 1998). The 2080del4 mutation
(Table 1) has been reported in several Dutch families and, more
recently, in two breast cancer patients of the unselected series in
the UK by Peto et al (1999). Other mutations include the BRCA1
G2508T and the BRCA2 3295insA, both found in a breast cancer
patient of Scottish descent (Liede et al, 1998). Only the 1294del40
and the 2800delAA mutations have been reported exclusively in
British and North American families. There were 15 entries for the
BRCA1 1294del40 mutation found in six centres in Britain and
North America (BIC, 1999). Neuhausen et al (1996) demonstrated
a conserved haplotype for six 1294del40 mutation families which
implied a common ancestral origin for the 1294del40 families of
British-Irish descent. Friedman et al (1994) first reported the
BRCA1 2800delAA mutation. The 2800delAA was also previ-
ously found in Scottish families, including an individual appar-
ently homozygous for the 2800delAA mutation (Boyd et al, 1995).
In this study of 17 distinct BRCA1 2800delAA families, we
provide evidence for a founder BRCA1 mutation specific to the
Scottish population.
The Scottish population is frequently described as being of
‘Celtic’ origin though the definition of Celtic is somewhat impre-
cise. The Celts are believed to have spread from the mainland of
Europe via Northern France and Spain to Cornwall, Wales, Ireland
and Scotland, beginning over 2000 years ago. There were
indigenous Scots who were displaced by, or who merged with, the
incoming Celts and in the intervening centuries Viking raiders and
other Scandinavian seafarers and fisherfolk have also added to the
population mix. In the study of breast–ovarian cancer families in
Wales, the BRCA1 2800delAA was not detected among 17 fami-
lies (Lancaster et al, 1998). However, culturally and linguistically
the Irish and Scottish Celts appear to have more in common with
each other than with present day Bretons, Cornish or Welsh.
Previous studies on the distribution of genetic polymorphisms,
such as HLA haplotypes, tend to place the Irish/Scottish ‘Celts’
somewhere between the modern day English and the Scandinavian
populations (Bodmer et al, 1987).
The present day Scottish population has expanded over the past
150 years from a somewhat depleted gene pool. The tendency of
both Scots and Irish to establish themselves in all parts of the
world is well recognized. There has been relatively little inward
migration in the past 200 years but a very substantial emigration,
principally to North America and Australia, during the mid nine-
teenth century, coinciding with the Highland ‘clearances’ when
large sections of the population were displaced from land they
occupied as tenant farmers. Several of the families ascertained in
Scotland for this study included relatives in North America and
Australia who have obtained counselling and screening as a result
of contacts maintained with their roots. Genotype and limited
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Figure 2 Pedigree of family UG475. Black circles indicate women affected with breast or ovarian cancer. Squares indicate men. Grey circles and squares
indicate individuals affected with cancers other than breast or ovarian cancer. Diagonal slash indicates deceased. Ov = ovarian cancer, Br = breast cancer,
Co = colorectal cancer, Lu = lung cancer, To = tongue cancer. The numbers following the abbreviations indicate ages of diagnosis. The plus sign indicates the
presence of a BRCA1 or BRCA2 mutation (indicated below symbol)haplotype analysis for key individuals belonging to families with
the BRCA1 2800delAA mutation showed that the 17 mutation-
positive families share the same BRCA1-linked haplotype.
Specifically, the ten BRCA1 2800delAA families from North
America were found to share the Scottish BRCA1 haplotype.
These included five families with reported Scottish ancestry and
four families where the index case reported ‘British’ ancestry
when less certain of the geographic origin of their family beyond
the British isles or ‘Anglo-Saxon’ ethnicity (Table 2). The shared
haplotype found between these families and the Scottish
2800delAA families supports a common ancestral origin.
Most of the BRCA1 2800delAA families appear to originate
from West Central Scotland (Figure 3). While 2800delAA families
have been identified through regional genetics clinics in Glasgow,
Edinburgh and Dundee/St Andrews, to date, the 2800delAA
mutation has not been identified in families from the Aberdeen
catchment area of the North East (Haites, personal communica-
tion). The reverse tendency was noted for Huntington’s disease,
where a concentration of affected families was traced to the North
East and attributed to a common founder, possibly of
Scandinavian fisher stock, who settled in Scotland some 300 years
ago (Lyon, 1962).
The woman reported by Boyd et al (1995) as a homozygous
mutant for the 2800delAA mutation is the proband of family
UG475 (Figure 2). We did not re-examine homozygous status of
the proband in this study. Interestingly, the proband’s maternal
cousin diagnosed with bilateral breast cancer does not carry the
BRCA1 2800delAA mutation, instead she was found to have a
BRCA2 8297delC mutation. Consequently, it remains unclear
which cancer cases in family UG475 are associated with a BRCA1
or  BRCA2 mutation or both. The BRCA2 8297delC is a novel
mutation detected in another Glasgow family UG12343 which
contains four cases of female breast cancer (ages 37, 47, 64, 64)
and one case of prostate cancer.
In Glasgow, Dundee/St Andrews and Edinburgh, a series of
breast–ovarian cancer families with evidence for a genetic predis-
position (e.g. two first- or second-degree relatives diagnosed with
breast cancer below age 50 or ovarian cancer) was tested and
six  BRCA1 2800delAA mutation families were identified.
Approximately 4% of at-risk Scottish families were found to have
the BRCA1 2800delAA mutation. The absence of the 2800delAA
mutation in a series of 100 non-cancer controls is consistent with
the pathogenic nature of the BRCA1 mutation.
The overall incidence of breast cancer in Scotland is relatively
high; the age-standardized rate (world) for Scotland is 72.70 per
100 000, whereas the rate for England and Wales is 68.84 per
100 000 (IARC, 1997). Information on the prevalence of BRCA1
and BRCA2 in breast and ovarian cancer incidence specific to
Scotland is not available. Larger population-based studies are
necessary to more accurately estimate the contribution of the
BRCA1 and  BRCA2 in the general breast and ovarian cancer inci-
dence in Scotland. Although further studies are necessary, we esti-
mate the frequency of the BRCA1 2800delAA mutation among
Scottish breast cancer patients diagnosed below age 50 could
reach 2%. The overall frequency of this mutation in the general
population in Scotland is expected to lie below 1%.
ACKNOWLEDGEMENTS
We acknowledge the contribution of patients to this study by
Drs Elaine Anderson and Marta Reis. We thank Elaine Jack,
Karen Robb, Elaine Kwan, Danny Vesprini, Gord Glendon,
Joanne Honneyford, Shelly Cummings, Maureen Seminsky and
Drs. David Goudie, Doug Horsman and Jackie Yule for technical
support. We thank Professor Neva Haites for personal communica-
tion and update of the Aberdeen regional genetics service.
Dr Mary-Claire King’s laboratory is funded by National Institutes
of Health grant R01 CA 27632. Alexander Liede is an MRC
(Canada) doctoral scholar.
REFERENCES
BIC (1998) Breast Cancer Information Core Database:
http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/
Bodmer JG, Kennedy LJ, Lindsay J and Wasik AM (1987) Applications of serology
and the ethnic distribution of three locus HLA haplotypes. Br Med Bull 43:
94–121
Boyd M, Harris F, McFarlane R, Davidson HR and Black DM (1995) A human
BRCA1 gene knockout. Nature 375: 541–542
Claus EB, Schildkraut JM, Thompson WD and Risch NJ (1996) The genetic
attributable risk of breast and ovarian cancer. Cancer 77: 2318–2324
Collyer S and De Mey R (1987) Public records and recognition of genetic disease in
Scotland. Clin Genet 31: 125–131
Easton DF, Ford D and Peto J (1993) Inherited susceptibility to breast cancer.
Cancer Surv 18: 1–17
Easton DF, Ford D and Bishop DT (1995) Breast and ovarian cancer incidence in
BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum
Genet 56: 265–271
Ford D, Easton DF, Bishop DT, Narod SA and Goldgar DE (1994) Risks of cancer
in BRCA1 mutation carriers. Lancet 343: 692–695
Ford D, Easton DF and Peto J (1995) Estimates of the gene frequency of BRCA1 and
its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:
1457–1462
710 A Liede et al
British Journal of Cancer (2000) 82(3), 705–711 © 2000 Cancer Research Campaign
Figure 3 Map of Scotland. The BRCA1 2800delAA families likely originated
from the Central Lowlands and Southern Uplands of Scotland. The BRCA1
2800delAA families were identified through regional genetics clinics in the
West Central region of Scotland (Glasgow, Edinburgh, Dundee and St
Andrews). One Toronto family (UT271) originated from the county of
Kirkudbrightshire (near Dumfries). To date, the 2800delAA mutation has not
been identified in families from the Aberdeen catchment area of the North
East (Haites, personal communication). Map was modified from Virtual
Tourist web-site: http://www.vtourist.com/Europe/United_Kingdom/ciafactsFriedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE and King
M-C (1994) Confirmation of BRCA1 by analysis of germline mutations linked
to breast and ovarian cancer in ten families. Nat Genet 8: 399–404
Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode
EL, Rowell SE and King M-C (1995) Novel inherited mutations and variable
expressivity of BRCA1 alleles, including the founder mutation 185delAG in
Ashkenazi Jewish families. Am J Hum Genet 57: 1284–1297
Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF and Ponder
BAJ (1997) Frequently occurring germ-line mutations of the BRCA1 gene in
ovarian cancer families from Russia. Am J Hum Genet 60: 1239–1242
IARC (1997) Cancer Incidence in Five Continents, Vol. VII. International Agency
for Research on Cancer: Lyon
Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA,
Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V
and Barkardottir RB (1996) High prevalence of the 999del5 mutation in
Icelandic breast and ovarian cancer patients. Cancer Res 56: 3663–3665
Lancaster JM, Carney ME, Gray J, Myring J, Gumbs C, Sampson J, Wheeler D,
France E, Wiseman R, Harper P and Futreal PA (1998) BRCA1 and BRCA2 in
breast cancer families from Wales: moderate mutation frequency and two
recurrent mutations in BRCA1. Br J Cancer 78: 1417–1420
Liede A, Rehal P, Vesprini D, Jack E, Abrahamson J and Narod SA (1998) A breast
cancer patient of Scottish descent with germ-line mutations in BRCA1 and
BRCA2. Am J Hum Genet 60: 1543–1544
Liu CY, Flesken-Nikitin A, Li S, Zeng Y and Lee WH (1996) Inactivation of the
mouse BRCA1 gene leads to failure in the morphogenesis of the egg cylinder in
early postimplantation development. Genes Dev 10: 1835–1843
Lyon RLL (1962) Huntington’s chorea in the Moray Firth area. Br Med J i:
1301–1306
Mullen P, Miller WR, Mackay J, Fitzpatrick DR, Langdon SP and Warner JP (1997)
BRCA1 5382insC in sporadic and familial breast and ovarian carcinoma in
Scotland. Br J Cancer 75: 1377–1380
Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson
G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F,
Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G,
Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King M-C and Goldgar DE
(1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in
61 families: results of an international study. Am J Hum Genet
58: 271–280
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG and King M-C (1998)
Frequency of breast cancer attributable to BRCA1 in a population-based series
of American women. J Am Med Assoc 279: 915–921
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C,
Deacon J and Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene
mutations in patients with early-onset breast cancer. Journal of the National
Cancer Institute 91: 943–949
Peelen T, van Vliet M, Petruj-Bosch A, Mieremet C, van den Ouweland AMW,
Hoervorst F, Brohet R, Ligtenberg MJL, Teugels E, van der Luijt R, van der
Hout AH, Gille JJP, Pals G, Jedema I, Olmer R, van Leeuwen I, Newman B,
Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJW, Bakker MM,
Willems HW, van der Looij E, Neyns B, Bonduelle M, Jansen R, Oosterwijk
JC, Sijmons R, Smeets HJM, van Asperen CJ, Meijers-Heijboer H, Klijn JGM,
de Greve J, King M-C, Menko FH, Brunner HG, Halley D, van Ommen G-JB,
Vasen HFA, Cornelisse CJ, van’t Veer LJ, de Knijff P, Bakker E and Devilee P
(1997) A high proportion of novel mutations in BRCA1 with strong founder
effects among Dutch and Belgian hereditary breast and ovarian cancer families.
Am J Hum Genet 60: 1041–1049
Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M,
Hogervorst FBL, Hageman S, Arts PJW, Ligtenberg MJL, Meijers-Heijboer H,
Klijn JGM, H.F.A. V, Cornelisse CJ, van’t Veer LJ, Bakker E, van Ommen
G-JB and Devilee P (1997) BRCA1 genomic deletions are major founder
mutations in Dutch breast cancer patients. Nat Genet 17: 341–345
Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B,
Ponder BAJ and Olah E (1997) Analysis of BRCA1 and BRCA2 mutations in
Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 60:
1242–1246
Roa BB, Boyd AA, Vocik K and Richards CS (1996) Ashkenazi Jewish population
frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:
185–187
Sinclair S (1990) Tracing your Scottish Ancestors: a Guide to Ancestry Research in
the Scottish Record Office. HMSO: Edinburgh
Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS and
Brody LC (1995) The carrier frequency of the BRCA1 185delAG mutation is
approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:
198–200
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M,
Timmerman MM, Brody LC and Tucker MA (1997) The risk of cancer
associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi
Jews. New Engl J Med 336: 1401–1408
Szabo CI and King M-C (1997) Population genetics of BRCA1 and BRCA2. Am J
Hum Genet 60: 1013–1020
Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG,
Tryggvadottir L, Tulinius H and Eyfjord JE (1997) Study of a single BRCA2
mutation with high carrier frequency in a small population. Am J Hum Genet
60: 1079–1084
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly
M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD,
Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin
B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA and
Garber JE (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in
Ashkenazi Jewish breast cancer families. Nat Med 2: 1179–1183
Tonin PN, Mes-Masson A-M, Futreal A, Morgan K, Mahon M, Foulkes WD, Cole
DEC, Provencher D, Ghadirian P and Narod SA (1998) Founder BRCA1 and
BRCA2 mutations in French Canadian breast and ovarian cancer families.
Am J Hum Genet 63: 1341–1351
Xu CF, Chambers JA, Nicolai H, Brown MA, Hujeirat Y, Mohammed S, Hodgson S,
Kelsell DP, Spurr NK, Bishop DT and Solomon E (1997) Mutations and
alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families.
Genes Chromosomes Cancer 18: 102–110
NOTE ADDED IN PROOF
Since the work was completed on the 17 breast and ovarian cancer
families with the BRCA1 2800delAA germline mutation (this
issue), we have learned of the existence of three additional fami-
lies with this mutation. One is a breast cancer patient from
Glasgow ascertained in an unselected series of early-onset breast
cancer patients in the UK as reported by Peto et al (1999). The
second is a breast cancer patient diagnosed at age 35, of Scottish
ancestry, reported to the BIC database by a group in London,
Ontario. The third subsequent occurrence of the 2800delAA is in a
breast cancer patient ascertained in Edinburgh who originated
from South West Scotland and Yorkshire (Table 3). We are
currently completing further molecular work on these three addi-
tional families. There is evidence to support that the BRCA1
2800delAA mutation can be traced to a set of ancestors in
Scotland.
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Table 3 Three additional families* with BRCA1 2800 delAA)
Family Centre Origin or ancestry Breast cancer Ovarian  Other cancers
total ≤50 >50 total
1 Peto et al (1999) Cambridge & Glasgow Glasgow, Scotland 1 1 0 0 none reported
2 Ainsworth et al (pers comm, BIC 1999) London, Ontario Scotland & England 2 2 0 0 stomach (1), colon (1)
3 Steel et al (pers comm) Edinburgh Scotland & Yorkshire 5 2 3 1 colon (1), prostate (1), lung (1)
*Families found after completion of study by Liede et al; genotype analysis currently underway.